BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Tomoya Yokota,Takashi Ura,N. Shibata,Daisuke Takahari,Kohei Shitara,M. Nomura,C. Kondo,Ayako Mizota,Setsuo Utsunomiya,Kei Muro,Yasushi Yatabe +10 more
TLDR
Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC, and the KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurring CRC.Abstract:
Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC) treated with anti-EGFR therapies This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advanced and recurrent CRC patients Patients with advanced and recurrent CRC treated with systemic chemotherapy (n=229) were analysed for KRAS/BRAF genotypes by cycleave PCR Prognostic factors associated with survival were identified by univariate and multivariate analyses using the Cox proportional hazards model KRAS and BRAF mutations were present in 345% and 65% of patients, respectively BRAF mutated tumours were more likely to develop on the right of the colon, and to be of the poorly differentiated adenocarcinoma or mucinous carcinoma, and peritoneal metastasis The median overall survival (OS) for BRAF mutation-positive and KRAS 13 mutation-positive patients was 110 and 277 months, respectively, which was significantly worse than that for patients with wild-type (wt) KRAS and BRAF (406 months) (BRAF; HR=425, P<0001, KRAS13; HR=203, P=0024) After adjustment for significant features by multivariate Cox regression analysis, BRAF mutation was associated with poor OS (HR=423, P=0019) Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC The KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurrent CRCread more
Citations
More filters
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Hiroya Takiuchi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara,Rectum +34 more
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Journal ArticleDOI
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
Antonio Marchetti,Lara Felicioni,Sara Malatesta,Maria Grazia Sciarrotta,Luigi Guetti,Antonio Chella,Patrizia Viola,Carmela Pullara,Felice Mucilli,Fiamma Buttitta +9 more
TL;DR: V600E mutations are significantly associated with female sex and represent a negative prognostic factor in patients with non-small-cell lung cancer and a number of other clinicopathologic parameters potentially useful for the selection of patients carrying BRAF mutations were identified.
Journal ArticleDOI
Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer
Ryan B. Corcoran,Chloe E. Atreya,Gerald Steven Falchook,Eunice L. Kwak,David P. Ryan,Johanna C. Bendell,Omid Hamid,Wells A. Messersmith,Adil Daud,Razelle Kurzrock,Mariaelena Pierobon,Peng Sun,Elizabeth Cunningham,Shonda M Little,Keith W. Orford,Monica Motwani,Yuchen Bai,Kiran Patel,Alan P. Venook,Scott Kopetz +19 more
TL;DR: The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant mCRC, and mutational analysis revealed that the patient achieving a complete response and two of three evaluable patients achieving a partial response had PIK3CA mutations.
Journal ArticleDOI
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
Takayuki Yoshino,Dirk Arnold,Hiroya Taniguchi,George Pentheroudakis,Kentaro Yamazaki,R. Xu,Tae Won Kim,Fuad Ismail,Iain Beehuat Tan,K.-H. Yeh,Axel Grothey,S.Z. Zhang,Joong Bae Ahn,M. Y. Mastura,D. Chong,L.-T. Chen,Scott Kopetz,Takako Eguchi-Nakajima,Hiromichi Ebi,A. Ohtsu,Andrés Cervantes,K. Muro,Josep Tabernero,Hironobu Minami,Fortunato Ciardiello,J.-Y. Douillard +25 more
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China, Korea, Malaysia, Singapore, Singapore and Taiwan.
Journal ArticleDOI
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Paul Lochhead,Aya Kuchiba,Yu Imamura,Xiaoyun Liao,Mai Yamauchi,Reiko Nishihara,Zhi Rong Qian,Teppei Morikawa,Jeanne Shen,Jeffrey A. Meyerhardt,Charles S. Fuchs,Shuji Ogino +11 more
TL;DR: Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification and no evidence existed for a differential prognostic role of BRAF mutation by MSI status.
References
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S. Karapetis,Shirin Khambata-Ford,Derek J. Jonker,Christopher J. O'Callaghan,Dongsheng Tu,Niall C. Tebbutt,R. John Simes,Haji Chalchal,Jeremy Shapiro,Sonia Robitaille,Timothy J. Price,Lois E. Shepherd,Heather-Jane Au,Christiane Langer,Malcolm J. Moore,John Zalcberg +15 more
TL;DR: Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Journal ArticleDOI
Mechanism of Activation of the Raf-Erk Signaling Pathway by Oncogenic Mutations of B-Raf
Paul T C Wan,Mathew J. Garnett,S. Mark Roe,Sharlene Lee,Dan Niculescu-Duvaz,Valerie M. Good,Cancer Genome,C. Michael Jones,Christopher J. Marshall,Caroline J. Springer,David Barford,Richard Marais +11 more
TL;DR: The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer,Igor Bondarenko,A. Makhson,Joerg T. Hartmann,Jorge Aparicio,Filippo de Braud,Serban Donea,Heinz Ludwig,Gunter Schuch,Christopher Stroh,Anja H. Loos,A. Zubel,Piotr Koralewski +12 more
TL;DR: KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.
Related Papers (5)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
Mutations of the BRAF gene in human cancer
Helen Davies,Graham R. Bignell,Charles Cox,Philip J. Stephens,Sarah Edkins,S. M. Clegg,Jon W. Teague,Hayley Woffendin,Mathew J. Garnett,William Bottomley,Neil Davis,Ed Dicks,Rebecca Ewing,Yvonne Floyd,Kristian Gray,S. Hall,Rachel Hawes,Jaime Hughes,Vivian Kosmidou,Andrew Menzies,Catherine Mould,Adrian Parker,Claire Stevens,Stephen Watt,Steven Hooper,Rebecca Wilson,Hiran Jayatilake,Barry A. Gusterson,Colin Cooper,Janet Shipley,Darren Hargrave,Kathy Pritchard-Jones,Norman J. Maitland,Georgia Chenevix-Trench,Gregory J. Riggins,Darell D. Bigner,Giuseppe Palmieri,Antonio Cossu,Adrienne M. Flanagan,Andrew G. Nicholson,Judy W. C. Ho,Suet Yi Leung,Siu Tsan Yuen,Barbara L. Weber,Hilliard F. Seigler,Timothy L. Darrow,Hugh Paterson,Richard Marais,Christopher J. Marshall,Richard Wooster,Michael R. Stratton,P. Andrew Futreal +51 more
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more